A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of Alpelisib BYL719 in Combination with Nab-Paclitaxel in Patients with Advanced Triple Negative Breast Cancer with Either Phosphoinositide-3-Kinase Catalytic Subunit Alpha PIK3CA Mutation or Phosphatase and Tensin Homolog Protein PTEN Loss Without PIK3CA Mutation
A Phase III Open-label, Randomised Study of Datopotamab Deruxtecan Dato-DXd With or Without Durvalumab Versus Investigator's Choice of Therapy in Patients With Stage I-III Triple-negative Breast Cancer Who Have Residual Invasive Disease in the Breast and/or Axillary Lymph Nodes at Surgical Resection Following Neoadjuvant Systemic Therapy TROPION-Breast03
A Phase III Trial Evaluating the Role of Exemestane Plus GnRH Analogue as Adjuvant Therapy for Premenopausal Women with Endocrine Responsive Breast Cancer
Phase III Study of Sacituzumab Govitecan IMMU-132 Versus Treatment of Physician's Choice TPC in subjects with Hormonal Receptor-Positive HR+ Human Epidermal Growth Factor Receptor 2 HER2 Negative Metastatic Breast Cancer MBC who have failed at least two prior chemotherapy regimens
Prospective evaluation of GErmline mutations, Cancer outcome and Tissue biomarkers P.R.O.G.E.C.T.: A registry for patients with triple negative breast cancer and germline mutations
A Phase III Clinical Trial Evaluating De-Escalation of Breast Radiation for Conservative Treatment of Stage I, Hormone Sensitive, HER2-Negative, Oncotype Recurrence Score </= 18 Breast Cancer DEBRA